Dáil Éireann Debate, Tuesday - 26 April 2022
1807. Deputy David Cullinane asked the Minister for Health the status of the inquiry and terms of reference for the drug sodium valproate; his plans to provide the disability package for those affected by sodium valproate; and if he will make a statement on the matter. [21053/22]
Amharc ar fhreagra1831. Deputy Patrick Costello asked the Minister for Health when the inquiry into the historic use of sodium valproate, announced in October 2020, will take place; and if he will make a statement on the matter. [21143/22]
Amharc ar fhreagraI propose to take Questions Nos. 1807 and 1831 together.
Department of Health officials are currently engaging with patient groups and other stakeholders regarding the terms of reference for an inquiry into the historical licensing and use of sodium valproate. The timeframe for the inquiry has yet to be decided. There is no specific package of supports available for people adversely affected by sodium valproate exposure in utero; however, the HSE has developed a diagnostic pathway for patients with suspected foetal valproate syndrome (FVS), as well as a pathway to community care services for those who receive a diagnosis of FVS.
